These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. A novel intronic splice site Bakšienė M; Benušienė E; Morkūnienė A; Ambrozaitytė L; Utkus A; Kučinskas V Balkan J Med Genet; 2016 Dec; 19(2):95-100. PubMed ID: 28289596 [TBL] [Abstract][Full Text] [Related]
25. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells. Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285 [TBL] [Abstract][Full Text] [Related]
26. A case of infantile Barth syndrome with severe heart failure: Importance of splicing variants in the TAZ gene. Takeda A; Ueki M; Abe J; Maeta K; Horiguchi T; Yamazawa H; Izumi G; Chida-Nagai A; Sasaki D; Tsujioka T; Sato I; Shiraishi M; Matsuo M Mol Genet Genomic Med; 2023 Jul; 11(7):e2190. PubMed ID: 37186429 [TBL] [Abstract][Full Text] [Related]
29. Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice. Russo S; De Rasmo D; Signorile A; Corcelli A; Lobasso S Sci Rep; 2022 Nov; 12(1):19847. PubMed ID: 36400945 [TBL] [Abstract][Full Text] [Related]
30. Decreasing cytosolic translation is beneficial to yeast and human Tafazzin-deficient cells. de Taffin de Tilques M; Lasserre JP; Godard F; Sardin E; Bouhier M; Le Guedard M; Kucharczyk R; Petit PX; Testet E; di Rago JP; Tribouillard-Tanvier D Microb Cell; 2018 Feb; 5(5):220-232. PubMed ID: 29796387 [TBL] [Abstract][Full Text] [Related]
31. Barth syndrome: A life-threatening disorder caused by abnormal cardiolipin remodeling. Raja V; Reynolds CA; Greenberg ML J Rare Dis Res Treat; 2017; 2(2):58-62. PubMed ID: 31032491 [TBL] [Abstract][Full Text] [Related]
33. Phosphokinome Analysis of Barth Syndrome Lymphoblasts Identify Novel Targets in the Pathophysiology of the Disease. Agarwal P; Cole LK; Chandrakumar A; Hauff KD; Ravandi A; Dolinsky VW; Hatch GM Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30002286 [TBL] [Abstract][Full Text] [Related]
34. Dietary linoleic acid supplementation fails to rescue established cardiomyopathy in Barth syndrome. Zhu S; Pang J; Nguyen A; Huynh H; Lee S; Gu Y; Vaz FM; Fang X J Mol Cell Cardiol Plus; 2024 Jun; 8():. PubMed ID: 38974772 [TBL] [Abstract][Full Text] [Related]
35. Re-Expression of Tafazzin Isoforms in TAZ-Deficient C6 Glioma Cells Restores Cardiolipin Composition but Not Proliferation Rate and Alterations in Gene Expression. Jagirdar G; Elsner M; Scharf C; Simm S; Borucki K; Peter D; Lalk M; Methling K; Linnebacher M; Krohn M; Wolke C; Lendeckel U Front Genet; 2022; 13():931017. PubMed ID: 35957687 [TBL] [Abstract][Full Text] [Related]
36. Tafazzin splice variants and mutations in Barth syndrome. Kirwin SM; Manolakos A; Barnett SS; Gonzalez IL Mol Genet Metab; 2014 Jan; 111(1):26-32. PubMed ID: 24342716 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of cardiolipin nanodisks as lipid replacement therapy for Barth syndrome. Ikon N; Hsu FF; Shearer J; Forte TM; Ryan RO J Biomed Res; 2018 Mar; 32(2):107-112. PubMed ID: 29336355 [TBL] [Abstract][Full Text] [Related]